Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Scientific Officer Barbara Louise Hibner
Salarius Pharmaceuticals Inc. has filed an initial statement of beneficial ownership for its Chief Scientific Officer, Barbara Louise Hibner. The filing is accessible via EDGAR, the SEC's system. This news brief was generated by Public Technologies using AI and is for informational purposes only, not financial advice.
Salarius Pharmaceuticals Inc. has filed an initial statement of beneficial ownership. The filing names Barbara Louise Hibner as the beneficial owner, who serves as the Chief Scientific Officer of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001615219-25-000187), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
